European CHMP recommends approval of an extension to the existing indication for nivolumab for non-small cell lung cancer

The CHMP has recommended its approval for use in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic NSCLC in adults whose tumours have no sensitising EGFR mutation or ALK translocation.


European Medicines Agency